FATE THERAPEUTICS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.6M | $13.6M | $63.5M | $96.3M | $55.8M |
| Research and development | $107.8M | $135.0M | $172.6M | $320.5M | $215.5M |
| Operating expenses | $154.3M | $223.9M | $254.0M | $404.7M | $272.8M |
| Operating income | -$147.7M | -$210.3M | -$190.5M | -$308.4M | -$217.0M |
| Interest expense | — | — | — | — | $0 |
| Income tax expense | $2,000 | $0 | $0 | $0 | $0 |
| Net income | -$136.3M | -$186.3M | -$160.9M | -$281.7M | -$212.2M |
| Balance Sheet | |||||
| Cash and equivalents | $46.6M | $36.1M | $41.9M | $61.3M | $133.6M |
| Current assets | $208.7M | $291.9M | $331.5M | $502.1M | $633.4M |
| Total assets | $318.9M | $440.7M | $506.2M | $705.6M | $921.5M |
| Current liabilities | $36.1M | $38.5M | $39.1M | $114.1M | $81.3M |
| Stockholders' equity | $207.2M | $318.7M | $368.4M | $483.9M | $678.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$106.1M | -$122.9M | -$132.3M | -$248.2M | -$162.9M |
| Depreciation and amortization | $12.9M | $19.0M | $18.3M | $13.8M | $5.8M |
| Stock-based compensation | $24.9M | $41.5M | $43.5M | $78.7M | $54.4M |
| Capital expenditure | $6.0M | $730,000 | $6.2M | $35.6M | $50.7M |
| Free cash flow | -$112.0M | -$123.6M | -$138.4M | -$283.8M | -$213.6M |
| Impairments | $0 | $13.4M | $0 | — | — |
Shares outstanding 116.6M · Free float 81.0%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.